• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Oramed Pharmaceuticals Inc.

    9/16/24 4:42:03 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ORMP alert in real time by email
    SC 13G 1 ormp13g.htm


    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G*
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED
    IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND
    (d) AND AMENDMENTS THERETO
    FILED PURSUANT TO RULE 13d-2
    (AMENDMENT NO.     )*

     Oramed Pharmaceuticals, Inc.
    (Name of Issuer)
     
     Common Stock par value $0.012 per share
    (Title of Class of Securities)
     
    68403P203
    (CUSIP Number)
     
    September 10, 2024
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     

     
    1
    NAMES OF REPORTING PERSONS
     
     
     BML Investment Partners, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     2,048,634
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     2,048,634
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     2,048,634
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     5.0
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     PN
     
     
     
     
     

    Item 1(a). Name of Issuer:

     Oramed Pharmaceuticals Inc.
     
    Item 1(b). Address of Issuer's Principal Executive Offices:

     1185 Avenue of the Americas, Third Floor,

    New York, NY

    Item 2(a). Name of Person Filing:

      BML Investment Partners, L.P

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     65 E Cedar, Suite 2
    Zionsville, IN 46077

    Item 2(c). Citizenship:

     Delaware

    Item 2(d). Title of Class of Securities:

     Common Stock
     
    Item 2(e). CUSIP Number:

     68403P203


    Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or
    240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):


    (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);


    (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);


    (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);


    (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);


    (e) ☐ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);


    (f) ☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);


    (g) ☐ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);


    (h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


    (i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


    (j) ☐ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);


    (k) ☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .
     
    Item 4. Ownership.


    (a) Amount beneficially owned: 
     2,048,634


    (b) Percent of class: 5.0


    (c) Number of shares as to which the person has:


    (i) Sole power to vote or to direct the vote:0


    (ii) Shared power to vote or to direct the vote:
     2,048,634

      (iii) Sole power to dispose or to direct the disposition of:0

      (iv) Shared power to dispose or to direct the disposition of:
     2,048,634
     


    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

    n/a
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     n/a

    Item 8. Identification and Classification of Members of the Group.

     n/a

    Item 9. Notice of Dissolution of Group.

     n/a
     
    Item 10.
    Certification.
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:September 16, 2024
     
     
    BML Captial Management, LLC
     
     
    By:
     /s/ Braden M Leonard
       
    Name:  Braden M Leonard
       
    Title:  Managing Member
     
     
    BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act.
     

    Get the next $ORMP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ORMP

    DatePrice TargetRatingAnalyst
    1/12/2023$30.00 → $3.00Buy → Hold
    Canaccord Genuity
    2/18/2022$20.00Overweight
    Cantor Fitzgerald
    11/30/2021$17.00 → $32.00Buy
    HC Wainwright & Co.
    11/29/2021$17.00 → $32.00Buy
    HC Wainwright & Co.
    11/2/2021$20.00 → $35.00Buy
    Aegis Capital
    7/29/2021$27.00 → $30.00Buy
    Canaccord Genuity
    More analyst ratings

    $ORMP
    SEC Filings

    View All

    Oramed Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)

    6/30/26 4:19:25 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Oramed Pharmaceuticals Inc.

    10-Q - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)

    5/19/26 5:08:29 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-Q filed by Oramed Pharmaceuticals Inc.

    NT 10-Q - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)

    5/15/26 4:05:30 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORMP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing

    HUDSON, Mass. and YOKNEAM ILLIT, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced that it has entered into a securities purchase agreement with a group of institutional and accredited investors participating in the strategic financing framework established earlier this year with Oramed Pharmaceuticals (NASDAQ:ORMP). "This financing reflects confidence in our strategy and the opportunity ahead," said Mark Grant, President and Chief Executive Officer of Lifeward. "We have built the clinical

    7/7/26 4:15:00 PM ET
    $LFWD
    $ORMP
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

    Significant Appreciation in Alpha Tau (NASDAQ:DRTS) Position (up ~$128 Million)Scilex (NASDAQ:SCLX) Loan Substantially RepaidTotal Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026)Oramed to Join the Russell 2000 and Russell 3000 Indexes this weekNEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repa

    6/25/26 11:35:00 AM ET
    $ORMP
    $DRTS
    $SCLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: Biological Products (No Diagnostic Substances)

    Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

    NEW YORK, June 17, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), announced today that it is set to join the U.S. small cap Russell 2000® and broad-market Russell 3000® Index at the conclusion of the 2026 Russell indexes semi-annual reconstitution. The 2026 Russell 2000 and Russell 3000 reconstitution becomes final after the close of US markets on Friday, June 26, and becomes effective for trading at the market open on Monday, June 29, according to a preliminary list of additions posted by FTSE Russell on May 22, 2026. Semi-annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of April 30, 2026, ranking them by total ma

    6/17/26 8:55:00 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    COO & CBO Hexter Joshua sold $611,431 worth of shares (137,000 units at $4.46) as part of a pre-agreed trading plan and exercised 50,000 shares at a strike of $3.69, decreasing direct ownership by 7% to 1,073,384 units (SEC Form 4)

    4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)

    7/2/26 5:00:11 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Gabay Avraham sold $330,744 worth of shares (73,360 units at $4.51) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 671,785 units (SEC Form 4)

    4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)

    7/2/26 5:00:07 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kidron Nadav

    4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)

    3/31/26 4:10:40 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oramed Pharmaceuticals downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Oramed Pharmaceuticals from Buy to Hold and set a new price target of $3.00 from $30.00 previously

    1/12/23 7:54:45 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Oramed Pharmaceuticals with a new price target

    Cantor Fitzgerald initiated coverage of Oramed Pharmaceuticals with a rating of Overweight and set a new price target of $20.00

    2/18/22 6:43:35 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Oramed Pharmaceuticals with a new price target

    HC Wainwright & Co. reiterated coverage of Oramed Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $17.00 previously

    11/30/21 7:36:11 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORMP
    Financials

    Live finance-specific insights

    View All

    Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

    Positions Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform's clinical development Provides Lifeward access to up to $47 million of capital HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that its shareholders approved the issuances of ordinary shares of the Company in connection with closing of the Co

    3/13/26 8:00:00 AM ET
    $LFWD
    $ORMP
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments

    Payment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty Interest NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) today announced it has received an $18 million payment from Scilex Holdings Inc., representing full satisfaction of obligations under the Option Agreement. This payment brings Oramed's current returns to $118 million on its original $99.5 million Scilex investment, with additional returns expected from the remaining convertible notes, warrants, and royalties. Oramed retains a $27 million note and a $12 million convertible note with Scilex, convert

    1/7/26 8:55:00 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oramed Reports Fiscal Third Quarter 2025 Financial Results

    Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million NEW YORK, Nov. 17, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, today announced its unaudited financial results for the nine months ended September 30, 2025. Nine-Month Period 2025 Financial Highlights: Net income (pre-tax) of $65.0 million, compared to a net loss of $6.1 million in the same period last yearCompleted

    11/17/25 8:56:00 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORMP
    Leadership Updates

    Live Leadership Updates

    View All

    Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

    Significant Appreciation in Alpha Tau (NASDAQ:DRTS) Position (up ~$128 Million)Scilex (NASDAQ:SCLX) Loan Substantially RepaidTotal Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026)Oramed to Join the Russell 2000 and Russell 3000 Indexes this weekNEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repa

    6/25/26 11:35:00 AM ET
    $ORMP
    $DRTS
    $SCLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: Biological Products (No Diagnostic Substances)

    Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

    NEW YORK, June 17, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), announced today that it is set to join the U.S. small cap Russell 2000® and broad-market Russell 3000® Index at the conclusion of the 2026 Russell indexes semi-annual reconstitution. The 2026 Russell 2000 and Russell 3000 reconstitution becomes final after the close of US markets on Friday, June 26, and becomes effective for trading at the market open on Monday, June 29, according to a preliminary list of additions posted by FTSE Russell on May 22, 2026. Semi-annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of April 30, 2026, ranking them by total ma

    6/17/26 8:55:00 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oramed Appoints Ben Shapiro to its Board of Directors

    NEW YORK, May 1, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) ("Oramed" or the "Company") (www.oramed.com) announced today the appointment of Mr. Benjamin Shapiro to its Board of Directors effective May 1, 2023. The Board determined that Mr. Shapiro qualifies as an independent director under the listing rules of the Nasdaq Capital Market.     Ben Shapiro is a successful entrepreneur and business professional who co-founded The Daily Wire, a successful, industry leading, international media outlet in June 2015. Since May 2015, he is host of "The Ben Shapiro Show," a popular podcast, and he is the author of numerous New York Times best-selling books. Mr. Shapiro earned

    5/1/23 4:45:00 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORMP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Oramed Pharmaceuticals Inc.

    SC 13G - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)

    9/16/24 4:42:03 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Oramed Pharmaceuticals Inc.

    SC 13D - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)

    3/22/24 9:30:27 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Oramed Pharmaceuticals Inc. (Amendment)

    SC 13D/A - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)

    9/2/21 4:49:56 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care